Amylyx Pharmaceuticals, Inc.
AMLX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $77 | $170 | $63 | $50 |
| Short-Term Investments | $99 | $201 | $284 | $46 |
| Receivables | $0 | $40 | $15 | $0 |
| Inventory | $0 | $38 | $10 | $0 |
| Other Curr. Assets | $12 | $15 | $10 | $9 |
| Total Curr. Assets | $189 | $465 | $382 | $105 |
| Property Plant & Equip (Net) | $3 | $6 | $8 | $0 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $1 | $46 | $1 | $0 |
| Total NC Assets | $4 | $53 | $9 | $1 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $194 | $517 | $391 | $106 |
| Liabilities | – | – | – | – |
| Payables | $3 | $22 | $6 | $4 |
| Short-Term Debt | $2 | $2 | $2 | $0 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $0 | $0 |
| Other Curr. Liab. | $24 | $58 | $38 | $13 |
| Total Curr. Liab. | $28 | $82 | $47 | $17 |
| LT Debt | $0 | $2 | $4 | $0 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $0 | $0 | $0 | $239 |
| Total NC Liab. | $0 | $2 | $4 | $239 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $2 | $4 | $6 | $0 |
| Total Liabilities | $29 | $84 | $51 | $257 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$607 | -$305 | -$354 | -$156 |
| AOCI | -$0 | $0 | -$0 | $0 |
| Other Equity | $772 | $738 | $695 | $5 |
| Total Equity | $165 | $433 | $341 | -$151 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $194 | $517 | $391 | $106 |
| Net Debt | -$75 | -$166 | -$56 | -$50 |